89 results about "Disease biomarker" patented technology

A gold nanoparticle-based assay for the detection of a target molecule, such as Hepatitis C Virus (HCV) RNA in serum samples, that uses positively charged gold nanoparticles (AuNPs) in solution based format. The assay has been tested on 74 serum clinical samples suspected of containing HCV RNA, with 48 and 38 positive and negative samples respectively. The developed assay has a specificity and sensitivity of 96.5% and 92.6% respectively. The results obtained were confirmed by Real-Time PCR, and a concordance of 100% for the negative samples and 89% for the positive samples has been obtained between the Real-Time PCR and the developed AuNPs based assay. Also, a purification method for the HCV RNA has been developed using HCV RNA specific probe conjugated to homemade silica nanoparticles. These silica nanoparticles have been synthesized by modified Stober method. This purification method enhanced the specificity of the developed AuNPs assay. The method can detect a target molecule, such as HCV RNA in serum, by employing modified silica nanoparticles to capture the target from a biological sample followed by detection of the captured target molecule using positively charged AuNPs. The assay is simple, cheap, sensitive and specific. Another aspect of the invention is anisotropic silver nanoparticles and methods of their use.

A system and methods, thereof, monitor biomarkers from a patient suffering from neural injury in real-time. The system comprises a quartz crystal microbalance wherein a capture molecule specific for certain biomarkers is diagnostic of the type of neural injury, location of neural injury and the degree of severity of neural injury. The system, in particular, provides real-time continuous monitoring of a patient.

The present invention discloses an image classification method based on a semi-multi-mode fusion feature reduction frame. Namely, a relation between a brain function and structure network feature vectors is maintained to better capture complementation information of a plurality of mode data and allow disease classification accuracy to be further improved. The method provided by the invention fullyexcavates reference information provided by structure network data, selects valid feature data from a brain function network feature vector matrix, and adds a new constraint on the basis of a known K-support normal form to remain distances of different mode feature data. Analysis and experiment results show that the image classification method based on the semi-multi-mode fusion feature reductionframe is better than known KSN and NF-KSN methods in the prior art. Consistency network connection selected in the invention comprehensively considers correlation of the structure and the function network layer with the diseases and is not limited in the function network layer, and the selected consistency network connection taken as disease biomarkers is higher in reliability.

The present disclosure includes methods for the identification of novel biomarkers for Alzheimer's disease. The methods involve genomic, proteomic, bioinformatic, immunochemical, and behavioral assays of 3xTg-AD mice.

The Medical Diagnostic Apparatus implements a physician-operated medical data analysis system for assisting a physician in identifying ailments and conditions which correlate to anomalies identified in a set of patient medical data relating to an identified patient. This system includes a plurality of biomarkers which relate to interpreting patient medical data and possible ailments associated with patient medical data. A data characterization module displays biomarkers selected by a physician and a set of patient medical data, collected from and about an identified patient, to compare the set of patient medical data with biomarkers of known ailments to enable the physician to identify an ailment representative of the patient medical data.

The present invention pertains to a nano-based sensing device (a sensor) comprising a nano-scale working electrode that can be used for the ultra-sensitive detection of blood analytes, disease biomarkers, and other target molecules. The present invention also pertains to a method for detecting analytes using the sensor as the sensor element of a microfluidic device.

The invention relates to a kit for a serum / plasma lncRNA marker related to stomach cancer. The serum / plasma lncRNA marker is combination of MALAT1 and HOTAIR, a primer is a primer for the MALAT1 and the HOTAIR, and the upstream primer sequence and the downstream primer sequence of the MALAT1 are SEQ No.1 and SEQ No.2; the upstream primer and the downstream primer of the HOTAIR are SEQ No.3 and SEQ No.4. By means of the kit, the defect that a kit only adopting one serum / plasma lncRNA as the tumor marker is low in sensitivity and specificity, so that the fault diagnosis rate and the rate of early gastric cancer diagnosis are greatly raised is overcome; by means of the kit, the sensitivity and specificity of disease diagnosis are enhanced, successful development of the lncRNA biological marker is beneficial to auxiliary diagnosis of stomach cancer and provides reference for research of biological markers of other diseases, lncRNA chip detection is adopted to obtain a serum / plasma lncRNA expression profile for disease specificity and abnormity expression, a qRT-PCR method is applied to conduct single verification, and dye method is adopted to conduct verification.

This invention pertains to development of a new animal model for Parkinson's Disease (PD) and to the discovery that elevated monoamine oxygenase B (MOA-B) expression and / or activity is a strong prognostic indicator for the disease. Accordingly, in certain embodiments, methods are provided for identifying a mammal at risk for Parkinson's disease. The methods typically involve determining level of expression or activity of monoamine oxidase B (MAO-B) in a sample from the mammal wherein an elevated level of MAO-B expression and / or activity as compared to a control (reference) is an indicator that the mammal has an increased likelihood of developing Parkinson's disease.

Certain embodiments of the invention are directed to a photothermal immunoassay employing a thermometer or colorimetric detection method for sensitive quantitative readout based on the photothermal effect provided by a detection reagent.

The invention discloses a bio-functionalized gold nano fluorescent probe and a preparation method thereof. The probe is characterized by containing detection antibodies or nucleic acid aptamers, and gold nanoparticles modified on surfaces of fluorescence dyes. The gold nano fluorescent probe can highly-efficiently identify disease biomarkers. The fluorescence dyes are in a quenched state. When mercapto group-containing compounds are added into a detection system, the fluorescent dyes highly-efficiently enriched on the surfaces of the gold nanoparticles are detached, thereby causing substantial activation of the fluorescent probe; and a fluorescent intensity is proportional to a concentration of the biomarkers in samples. The method provided by the invention greatly increases a detection sensitivity of the disease biomarkers, and simultaneously has advantages of simple equipment, easy operation and batch testing.

The invention provides a disease biomarker screening analysis method, a disease biomarker screening analysis platform, a server and a disease biomarker screening analysis system, wherein the disease biomarker screening analysis method comprises the following steps of: receiving an analysis instruction, wherein the analysis instruction includes sample screening conditions and analysis program parameters; obtaining clinical information of samples to be analyzed corresponding to the sample screening conditions according to the sample screening conditions, and obtaining relevant biological information according to the clinical information of the samples to be analyzed; sending the clinical information of the samples to be analyzed, the relevant biological information and the analysis program parameters to the server so as to analyze the clinical information of the samples to be analyzed and the relevant biological information; receiving an analysis result returned by the server, and performing significance inspection on the analysis result; and if the analysis result is non-significant, resetting screening conditions, and performing analysis again until the analysis result is significant. The method provides a platform associating the clinical information with genome information for the genome research aspect, and the great-sample-size gene verification experiment is facilitated.

The Patient Data Management System operates under the control of a physician to implement a patient-specific instance of the apparatus which is capable of accessing at least one data manipulation module, each defining at least one process for transforming patient medical data pursuant to a predefined schema. A patient medical data processor is responsive to the physician selecting a set of patient medical data, at least one of the data manipulation modules, and an order of applying the selected data manipulation modules to the selected patient medical data for processing the selected patient medical data using the selected data manipulation modules in the selected order to identify data indicative of a predetermined condition in the selected patient medical data. A display is available for presenting a visualization of the data indicative of a predetermined condition in the selected patient medical data.

The present invention relates to an isolated chimeric molecule comprising a degradation domain including a eukaryotic U-box motif and a targeting domain capable of immuno specifically directing the degradation domain to a substrate where the targeting domain is heterologous to the degradation domain. A linker couples the degradation domain to the targeting domain. Also disclosed are compositions as well as methods of treating a disease, substrate silencing, screening agents for therapeutic efficacy against a disease, and methods of screening for disease biomarkers.

A method and apparatus for the integration of an ultrasound transducer with a SPECT imaging system is disclosed. The ultrasound transducer allows the delivery of particle-born drug therapies or thermally active therapies at the same site detected with SPECT imaging. The system includes a SPECT imaging subsystem; an ultrasound transducer for producing a signal representative of applied ultrasound and signally coupled to the SPECT imaging subsystem; and co-registering means for co-registering the signal representative of applied ultrasound in a coordinate system of SPECT imaging subsystem. The SPECT subsystem may be replaced with a SPECT / CT combined system to provide morphology that allows for treatment planning. In another embodiment, the ultrasound transducer can be used intermittently with the sequential gathering of SPECT images for tracking time-varying properties of the binding of specific SPECT contrast agents to biomarkers of disease. In this way, the ultrasound and SPECT imaging devices form a novel combination to improve patient care through improved spatial registration, therapy planning, and workflow.

The invention belongs to the field of the genetic engineering, and particularly provides a blood DNA (Deoxyribonucleic Acid) methylation marker for evaluating an early abortion risk, a primer and theapplication thereof. The DNA methylation marker comprises eight DNA methylation sites positioned near a PRDM1 gene transcription starting area: cg25608130, cg19577529, cg10573915, cg11072009, cg02667677, cg23778363, cg24793124 and cg07331652. The successful development of the category of the differentiated DNA methylation biological marker is the overturn of a traditional biomarker which gives a priority to protein, a brand new situation is started for diagnosing, preventing and curing the early abortion, and a reference is provided for researching the biomarkers of other diseases. The DNA methylation marker has the advantages of abundant raw materials and convenience in operation and is the biomarker with prospect.

The invention discloses an ultrahigh-sensitivity probe for disease marker or pathogen detection, as well as a preparation method and application of the ultrahigh-sensitivity probe. The light absorption value of the probe changes based on the collection of a plurality of gold nanoparticles. The probe mainly comprises two major parts, namely bio-functionalized magnetic bead nano microspheres and a gold nanoparticle composite solution. The probe is characterized by containing a detection antibody (Ab2) or a nucleic acid aptamer, biological enzyme active substance surface modified magnetic bead nanoparticles, a substrate which can be catalyzed by enzymes and gold nanoparticles. The ultrahigh-sensitivity probe can be efficiently distinguished from a disease biomarker, and biological enzyme active substances adhered to the surfaces of the magnetic bead nano microspheres can degrade the substrate which can be catalyzed by the biological enzyme active substances into a product with positive charges to collect the gold nanoparticles, so that the light absorption value of the gold nanoparticle solution is changed. According to the method, the detection sensitivity of the disease biomarker is greatly improved; in addition, the method has the advantages of simplify in equipment, simplicity in operation and batch detection capability.

The invention belongs to the field of the genetic engineering, and particularly provides a group of DNA methylation biomarkers for evaluating cardiac muscle cell damage and an application thereof. TheDNA methylation biomarker comprises 30 DNA methylation sites of 5 DMRs corresponding to 5 cardiac muscle differentiation key factors; and the five cardiac muscle differentiation key factors are GATA4, TNNT2, TNNI3, MEF2A and NKX2-5. Such type of the provided differential DNA methylation biomarkers is successfully developed to subvert the traditional biomarkers using protein as major means, a newsituation is created for the prevention and treatment of the cardiac muscle damage, and a reference is provided for the development of other disease biomarkers. The DNA methylation biomarkers are capable of evaluating the damage level of the cardiac muscle affected by environmental factors, and evaluating and forecasting the cardiotoxicity of environmental chemistry, and are the biomarkers with the prospect.

The present invention relates to a biomarker for Parkinson's disease. The biomarker and products associated with the biomarker may be used to assist diagnosis or to assess onset and / or development of Parkinson's disease. The invention also relates to use of the biomarker in clinical screening, assessment of prognosis, evaluation of drug treatments, drug screening or drug development in the field of Parkinson's disease and Parkinson's disease related disorders.

The present application relates to methods and systems of identifying molecules or processes of biological interest by using knowledge discovery in biological data. In particular, the present application describes new methods of creating a biological map, new methods of codifying such map, new methods of analyzing such map and new methods of identifying molecules and processes of biological interest. The present application provides methods and systems to identify new and useful direct or indirect therapeutic targets, molecular modulators, adverse events effectors, disease biomarkers, genetic biomarkers, safety-related biomarkers, diagnostic molecules, hormones, metabolites, or metabolic effectors of any type.

The invention provides an application of miRNA marker hsa-miR-486-5p. A serum micro ribonucleic acid marker provided by the invention as a CWP early diagnosis marker has the advantages that serum miRNAs are novel biomarkers, are different from traditional biomarkers, and have the advantages of being stable, minimally invasive, easy to detect, accurate to quantify and the like, the sensitivity and the specificity of disease diagnosis are greatly improved, a new situation is created for early diagnosis of CWP by successful development of micromolecular RNA biomarkers, and reference is provided for development of other disease biomarkers.

The invention relates to a Parkinson's disease biomarker and application thereof. The invention provides the biomarker for Parkinson's disease. The biomarker is circular RNA. The circular RNA is circ-AMOTL1, and the circ-AMOTL1 is a nucleotide sequence as shown in SEQ ID NO:1. The invention provides a method for early diagnosis of Parkinson's disease or related diseases and prediction of disease risk, and can solve the disadvantages that existing Parkinson's disease diagnosis methods cannot realize early warning and cannot predict Parkinson's disease.

The invention relates to a Parkinson's disease biomarker and application thereof, and belongs to the technical field of medical diagnosis. The biomarker comprises the methylation degree of at least one gene locus in the genes of GPR183, WDR46, PFDN6, SGCE, PEG10, EMX2OS, NFATC4, GJB1, IGF1R, UBAC2, ICA1L, ACRC, PAX6, ALX4, HIST1H4C, HSPA1L, LOC645323, BCYRN1, IGF2BP3, ZNF808, OTUD6A, NELL2, TAF1, EMX2, ARHGAP6, and RALYL. Only the methylation site of the Parkinson's disease biomarker needs to be directionally detected, the experimental method and the judgment method can be standardized, and misdiagnosis caused by human subjective deviation is avoided. Moreover, the Parkinson's disease biomarker can be detected from biological samples such as peripheral blood before the motor symptom of a patient attacks, so that the aim of early diagnosis can be fulfilled.

The invention relates to the field of use of a biomarker for a disease, and discloses biomarkers von willebrand Factor (VWF) and ADAMTS13 and use thereof in a cirrhosis diagnosis reagent. The VWF disclosed by the invention is formed by protein of which the accession number of an amino acid sequence in a database for the national center of biotechnology information (NCBI) is GI317373549; the ADAMTS13 is formed by protein of which the accession number in the database for the NCBI is GI74749836. A testee is subjected to cirrhosis diagnosis by the biomarkers VWF and ADAMTS13, and the biomarkers have the advantages of being simple and feasible, safe and free of a wound in the diagnosis process, easy to be accepted by a patient, small in effect on diagnostic criteria unification caused by personal subjective factors, high in specificity and sensitivity on diagnosis result, easy to carry out a lot of screening for selection, and the like.

The present application relates to an isolated chimeric molecule comprising a degradation domain comprising an E3 ubiquitin ligase (E3) motif and a targeting domain capable of specifically directing the degradation domain to a substrate, where the targeting domain is heterologous to the degradation domain. A linker couples the degradation domain to the targeting domain. Also disclosed are compositions as well as methods of treating a disease, substrate silencing, screening agents for therapeutic efficacy against a disease, and methods of screening for disease biomarkers.

The state of protein phosphorylation and glycosylation can be key determinants of cellular physiology such as early stage cancer, but the development of phosphoproteins and / or glycoproteins in biofluids for disease diagnosis remains elusive. Here we demonstrate, for the first time, a strategy to isolate and identify phosphoproteins / glycoproteins in extracellular vehicles (EVs) from human plasma as potential markers to differentiate disease from healthy states. We identified close to 10,000 unique phosphopeptides in EVs by isolating from small volume of plasma samples. Using label-free quantitative phosphoproteomics, we identified 144 phosphoproteins in plasma EVs that are significantly higher in patients diagnosed with breast cancer than in healthy controls. Several novel biomarkers were validated in individual patients using Paralleled Reaction Monitoring for targeted quantitation. Similarly a group of glycoproteins in plasma EVs are identified. The study demonstrated that the development of phosphoproteins and / or glycoproteins in plasma EV as disease biomarkers is highly feasible and may transform cancer screening and monitoring.